
Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc.(BLPH)内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签;可在本季度与近12个月之间切换;下方为季度图与交易明细。
SEC EDGAR · FMP · BLPH · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
3
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Bellerophon Therapeutics, Inc.内部人在过去近12个月主要在卖出股份,卖出行为通常由预设的Rule 10b5-1计划驱动,不一定代表对公司的负面看法。
▸ 数据来源:SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
BLPH 季度内部人买卖趋势
BLPH 内幕交易卖出 · BLPH 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源:SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
BLPH 高管卖出股份 · BLPH 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Oct 13, 2023 | Puissance Capital Management LP 10 percent owner | Sale | 1,076,841 | $112K | Form 4 |
| Jun 7, 2023 | Amin Naseem Director | Award | 47,578 | — | Form 4 |
| Jun 7, 2023 | Puissance Life Science Opportunities Fund VI 10 percent owner | Sale | 134,421 | $112K | Form 4 |
| May 18, 2023 | Kim Bobae VP Reg. Affairs & Quality | Option | 1,022 | $8K | Form 4 |
| May 18, 2023 | Kim Bobae VP Reg. Affairs & Quality | Sale | 9,455 | $95K | Form 4 |
| May 18, 2023 | Kim Bobae VP Reg. Affairs & Quality | Option | 266 | $2K | Form 4 |
| May 18, 2023 | Puissance Life Science Opportunities Fund VI 10 percent owner | Sale | 560,000 | $5.30M⚡ | Form 4 |
| Feb 10, 2023 | Amin Naseem Director | Award | 84,000 | — | Form 4 |
| Dec 9, 2022 | Dekker Martin Director | Other | 7,834 | $7K | Form 4 |
| Dec 9, 2022 | Shah Parag Suresh Director | Other | 7,834 | $7K | Form 4 |
| Dec 9, 2022 | Laccona Nicholas Director | Other | 5,530 | $5K | Form 4 |
| Dec 9, 2022 | Fernandes Peter Director | Other | 9,985 | $9K | Form 4 |
| Dec 31, 2021 | Amin Naseem Director | Award | 39,032 | — | Form 4 |
| Jun 7, 2021 | Puissance Life Science Opportunities Fund VI 10 percent owner | Award | 8,189 | $33K | Form 4 |
| Apr 26, 2021 | Puissance Life Science Opportunities Fund VI 10 percent owner | Award | 609,231 | $2.44M⚡ | Form 4 |
| Mar 31, 2021 | Peacock Jonathan M Director | Award | 15,308 | — | Form 4 |
| Mar 18, 2021 | New Mountain Investments II, LLC 10 percent owner | Sale | 400,000 | $2.19M⚡ | Form 4 |
| Sep 10, 2020 | FARES Wassim Chief Medical Officer | Purchase | 4,000 | $41K | Form 4 |
| Jun 8, 2020 | Wang Theodore T Director | Purchase | 2,600 | $33K | Form 4 |
| Jun 5, 2020 | Wang Theodore T Director | Purchase | 4,986 | $63K | Form 4 |
| May 21, 2020 | Puissance Life Science Opportunities Fund VI 10 percent owner | Award | 1,153,846 | $15.00M⚡ | Form 4 |
| Apr 17, 2020 | Puissance Cross-Border Opportunities III LLC 10 percent owner | Other | 553,250 | — | Form 4 |
| Jan 23, 2020 | Peacock Jonathan M Director | Award | 350,000 | — | Form 4 |
| Nov 25, 2019 | Wang Theodore T Director | Purchase | 7,193 | $3K | Form 4 |
| Nov 22, 2019 | Wang Theodore T Director | Purchase | 1,050 | $394 | Form 4 |
Puissance Capital Management LP
10 percent owner
日期
Oct 13
股数
1,076,841
均价
$0.10
总金额
$112K
Puissance Life Science Opportunities Fund VI
10 percent owner
日期
Jun 7
股数
134,421
均价
$0.83
总金额
$112K
Puissance Life Science Opportunities Fund VI
10 percent owner
日期
May 18
股数
560,000
均价
$9.46
总金额
$5.30M ⚡
Puissance Life Science Opportunities Fund VI
10 percent owner
日期
Jun 7
股数
8,189
均价
$4.00
总金额
$33K
Puissance Life Science Opportunities Fund VI
10 percent owner
日期
Apr 26
股数
609,231
均价
$4.00
总金额
$2.44M ⚡
New Mountain Investments II, LLC
10 percent owner
日期
Mar 18
股数
400,000
均价
$5.48
总金额
$2.19M ⚡
Puissance Life Science Opportunities Fund VI
10 percent owner
日期
May 21
股数
1,153,846
均价
$13.00
总金额
$15.00M ⚡
Puissance Cross-Border Opportunities III LLC
10 percent owner
日期
Apr 17
股数
553,250
均价
—
总金额
—
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源:SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BLPH 内幕交易
BLPH 内幕交易
Bellerophon Therapeutics, Inc.(BLPH)内幕交易数据来源于公司内部人(包括BLPH)提交的SEC Form 4申报文件。过去12个月内,0位内部人向SEC提交了交易申报。BLPH内部人近期主要在卖出,这可能反映预设的10b5-1计划执行,而非方向性判断。
如需查看Bellerophon Therapeutics, Inc.机构持仓比例和内部人持股百分比,请访问持仓(Ownership)标签页 → Ownership tab →
常见问题
BLPH 内幕交易 · 5个问题Bellerophon Therapeutics, Inc.(BLPH)的内部人包括高管和董事,如BLPH等。过去12个月内,0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源:FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026